You Feel Pain Differently. Your Genes Explain Why.

COMT is the enzyme that clears catecholamines (dopamine, norepinephrine, epinephrine) from your brain and nervous system. Think of it as the cleanup crew after a stress response. When COMT is working efficiently, it removes these signaling molecules quickly, allowing your nervous system to return to calm. If COMT is slow, these molecules linger, keeping your nervous system in a heightened state of alert.

The Val158Met variant of COMT is extremely common. Roughly 25% of people of European ancestry carry two copies of the slow variant (homozygous slow). If you’re slow at this position, your prefrontal cortex maintains higher baseline dopamine and norepinephrine levels. That means your nervous system stays in a more sensitive, reactive state even at rest. Pain signals get amplified before they even reach your conscious mind.

You probably notice this in your daily life. A noise that others barely register makes you wince. Bright light after being indoors feels harsh. And pain, whether from injury or chronic conditions, feels more intense and takes longer to fade. Your nervous system is essentially set to a higher gain setting.

Your body produces its own opioids called endogenous opioids (endorphins and enkephalins). These natural painkillers bind to opioid receptors scattered throughout your nervous system, dampening pain signals before they reach your brain. OPRM1 encodes the mu-opioid receptor, the main receptor where these natural painkillers do their work.

The A118G variant of OPRM1 changes the structure of the mu-opioid receptor slightly. The G allele, carried by roughly 10-15% of people of European ancestry (though much higher in East Asian ancestry at around 40%), creates a receptor that binds endogenous opioids less efficiently. Your body produces normal levels of natural painkillers, but your receptors don’t hear them as well. It’s like having the volume turned down on your body’s own pain-relief system.

This means you have a naturally higher pain threshold and less effective endogenous pain relief. Injuries that would send someone with the common A allele to bed might only inconvenience you for a few hours. But it also means you feel chronic pain more intensely because your body’s built-in opioid-based analgesia is working below its potential. You may also notice that standard opioid medications are less effective for you if you ever need them.

MTHFR is the enzyme that converts folate into methylfolate, a key methyl donor for dozens of downstream reactions in your body. One of those reactions is the synthesis of nitric oxide (NO), the molecule that regulates blood vessel tone and blood flow. Proper nitric oxide signaling is essential for migraines and vascular pain sensitivity.

The C677T variant of MTHFR, carried by roughly 40% of people of European ancestry, reduces enzyme efficiency by 40-70%. This impairs both methylation overall and specifically impairs nitric oxide synthesis. You end up with both reduced methylation capacity and dysregulated vascular tone. Your blood vessels become more reactive to pain triggers, and your nervous system has fewer methylation substrates to build protective neurotransmitters.

If you have this variant, you probably notice migraines that feel vascular in nature (throbbing, one-sided, with nausea). You might be sensitive to certain foods that trigger vasodilation. And you may notice that standard pain management fails because the root issue is vascular reactivity, not just pain signaling. Your nervous system is essentially operating with insufficient fuel for its own protective mechanisms.

BDNF (brain-derived neurotrophic factor) is a protein that tells neurons how to grow, connect, and respond to stimulation. In pain processing, BDNF is a double-edged sword. Low BDNF impairs your nervous system’s ability to learn and adapt, which sounds protective but actually makes you vulnerable to chronic pain because you can’t unlearn pain responses. High BDNF, particularly at certain sites in the spinal cord and brain, can amplify pain signaling through a process called central sensitization, where your nervous system becomes progressively more reactive to the same stimulus.

The Val66Met variant of BDNF, carried by roughly 30% of the population, affects how much BDNF is released in response to neural activity. Met allele carriers have reduced activity-dependent BDNF release, which impairs the brain’s ability to update pain-related memories and may predispose to chronic pain states. Once pain becomes chronic in your system, your brain has a harder time reverting to normal pain processing.

You might notice that acute injuries take longer to resolve into normal pain memories. Pain that should fade instead seems to establish itself as a permanent feature. You may have fibromyalgia or widespread pain that doesn’t match tissue damage. Your nervous system is essentially stuck in a pain-learning mode where normal recovery isn’t happening.

TRPV1 is a pain receptor on sensory nerve endings throughout your body. It’s activated by heat (above 43 degrees Celsius), by capsaicin (the compound that makes chili peppers burn), by low pH (acidity), and by inflammatory molecules. When activated, TRPV1 signals “pain” to your spinal cord and brain. TRPV1 variants determine the activation threshold for this receptor, essentially setting how sensitive you are to these pain triggers.

Gain-of-function variants in TRPV1, carried by roughly 25-30% of the population, lower the activation threshold for this receptor. Your TRPV1 receptors fire more easily in response to heat, pressure, and inflammatory chemicals, making you experience these stimuli as painful at lower intensities than someone with wild-type TRPV1. You might notice this as heightened sensitivity to spicy foods, discomfort in hot environments, and pain from light pressure or touch that others don’t perceive as painful.

If you have a gain-of-function TRPV1 variant, you likely feel pain from textures, temperatures, and sensations that others tolerate easily. You may avoid certain foods, clothing, or activities because they’re painful rather than merely uncomfortable. This isn’t weakness or anxiety; your pain receptors literally have a lower threshold.

GCH1 encodes the enzyme that synthesizes tetrahydrobiopterin (BH4), a critical cofactor for multiple neurotransmitter synthesis pathways. BH4 is essential for making serotonin, dopamine, and nitric oxide, all of which are involved in pain modulation and pain inhibition. Without adequate BH4, your nervous system cannot efficiently produce the neurochemical signals that suppress pain.

Variants in GCH1, carried by roughly 15-20% of the population, impair BH4 synthesis. Your nervous system literally has less raw material to build pain-suppressing neurotransmitters. This is particularly problematic in chronic pain and fibromyalgia, where the normal pain-inhibition pathways are already struggling. You end up with a nervous system that can’t manufacture enough of its own pain relief.

You might notice that pain seems to originate from nowhere, that there’s no clear tissue damage but the pain is real and severe, and that your pain seems to get worse under stress (when BH4 demand increases). Standard pain medications might help, but they’re addressing symptoms downstream of the real problem, which is insufficient BH4-dependent neurotransmitter production.